EUVIMEDEUVIMED entdecken
Crossref

Tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone in multiple myeloma treatment

Jingyi Bi, Xuelin Dou, Ruqi Liang, Lei Wen, Yang Liu, Xiaoguang Lei, Liru Wang, Huixia Guo, Xiaojun Huang, Mingdi Wang, Jin Lu

Acta Haematologica · 2025

DOI: 10.1159/000545709 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, 2025. Verfasst von Jingyi Bi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, C…. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols, Hydroxamic Acids. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We conducted a single-arm, open-label dose-exploration study to evaluate the safety and efficacy of the histone deacetylase inhibitor tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone (C-PDD) in treating relapsed and refractory multiple myeloma (RRMM) patients.

Methods

Eighteen patients were enrolled from August 2020 to May 2021, receiving 21-day cycles of C-PDD.

Results

Eighteen cases were analyzed, with a median prior treatment line of 2 (range: 1-4). The median number of completed treatment cycles was 4 (range: 1-8). The overall response rate was 57%, including 14% complete response, 14% very good partial response, and 29% partial response. Both bortezomib-sensitive and refractory groups had a response rate of 57%. The response rate was 100% in patients with extramedullary extraosseous involvement. The median follow-up was 42 months (range: 3-44), with median progression-free survival of 7 months and median overall survival of 24.5 months. Grade 3-4 hematologic adverse events included thrombocytopenia (50%), neutropenia (33%), and anemia (33%). Non-hematologic adverse events were mostly grade 1-2, with one case of grade 3 peripheral sensory neuropathy.

Conclusion

The C-PDD regimen showed efficacy in RRMM, including bortezomib-refractory disease and EME patients. The optimal dose and combination need to be explored in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsHydroxamic AcidsHumansBortezomibMaleFemaleDoxorubicinDexamethasoneMiddle AgedAgedAdultAged, 80 and overTreatment OutcomePolyethylene Glycols

Stichwörter der Autor:innen

BortezomibRelapsed and/or refractory multiple myelomaTucidinostat

Substanzen

BortezomibDoxorubicinDexamethasoneliposomal doxorubicinHydroxamic AcidsPolyethylene Glycols

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China.
  • Peking University College of Chemitry and Molecular Engineering, Beijing, China.
  • Fuxing Hospital, Capital Medical University, Beijing, China.
  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China, 5290675@qq.com.
  • Hematology Department, Peking University Shougang Hospital, Beijing, China, 5290675@qq.com.
  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China, lujin@pku.edu.cn.

Zitieren

APA

Bi, J., Dou, X., Liang, R., Wen, L., Liu, Y., Lei, X., Wang, L., Guo, H., Huang, X., Wang, M., & Lu, J. (2025). Tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone in multiple myeloma treatment. Acta Haematologica. https://doi.org/10.1159/000545709

Vancouver

Bi J, Dou X, Liang R, Wen L, Liu Y, Lei X, et al. Tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone in multiple myeloma treatment. Acta Haematologica. 2025. doi:10.1159/000545709

BibTeX
@article{Bi2025,
  author = {Bi, Jingyi and Dou, Xuelin and Liang, Ruqi and Wen, Lei and Liu, Yang and Lei, Xiaoguang and Wang, Liru and Guo, Huixia and Huang, Xiaojun and Wang, Mingdi and Lu, Jin},
  title = {Tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone in multiple myeloma treatment},
  journal = {Acta Haematologica},
  year = {2025},
  doi = {10.1159/000545709}
}
Kostenlos starten →